203|280|Public
500|$|... 1954: Norwegian {{pathologist}} Reidar Eker bred {{a line of}} Wistar rats {{predisposed to}} renal adenomas. The Eker rat became an important model of dominantly <b>inherited</b> <b>cancer.</b>|$|E
50|$|In 1999 genetic {{variations}} of CHEK2 {{were found to}} correspond to <b>inherited</b> <b>cancer</b> susceptibility.|$|E
5000|$|... various <b>inherited</b> <b>cancer</b> syndromes, {{particularly}} breast, thyroid, endocrine, gastrointestinal, urologic cancers, and Cowden syndrome ...|$|E
40|$|In {{last ten}} years, {{significant}} advances {{have occurred in}} thyroid endocrinology, {{as a consequence of}} the generalized use of molecular biology techniques. New genes involved in the development of thyroid cancer have been identified, which had a great impact on our understanding of thyroid cancer predisposition. All cancers are genetic in origin because they arise from mutations in a single somatic cell, but the genetic changes in sporadic cancers are confined to a particular tissue. In <b>inherited</b> <b>cancers,</b> a predisposing mutation is present in all somatic cells and in the germ line, which enables the transmission of risk to the next generation. Cancer genetics offers a model of how information on the genetics of <b>inherited</b> <b>cancers</b> could affect identification of individuals at increased genetic risk...|$|R
40|$|<b>Inherited</b> breast <b>cancer</b> is a {{heterogenous}} {{group of}} diseases. We examined this heterogeneity in a prospective series of inherited breast and ovarian cancers, previously demonstrated to include 84 % of <b>inherited</b> <b>cancers.</b> Ninety-two tumours (65 breast and 27 ovarian) in 82 patients from 70 kindreds were prospectively diagnosed. Fifteen {{of the breast}} cancers were in situ, 50 were infiltrating. 40 (49 %) of the 82 women carried a BRCA 1 mutation, whereas no mutation in BRCA 2 was found. Approximately, two-thirds of the BRCA 1 mutation carriers {{had one of the}} four most frequent Norwegian founder mutations. Ninety-five per cent of the epithelial ovarian cancers occurred in BRCA 1 mutation carrying women versus 38 % of infiltrating breast cancers and 7 % of carcinoma in situ of the breast. The BRCA 1 syndrome was phenotypically distinct with invasive, high grade, oestrogen receptor-negative breast cancers and epithelial ovarian cancers. Non-BRCA 1 / 2 <b>inherited</b> breast <b>cancers</b> included carcinoma in situ and lobular carcinoma and were frequently bilateral. Non-BRCA 1 / 2 <b>inherited</b> breast <b>cancer</b> is not associated with epithelial ovarian cancer and in breast cancers has distinct biological characteristics, indicating that the different subgroups of <b>inherited</b> breast <b>cancer</b> may need different healthcare services...|$|R
50|$|Some current {{tests for}} genetic {{diseases}} include: Cystic Fibrosis, Tay Sachs Disease, Lou Gehrig’s Disease (ALS), Huntington’s Disease, catastrophically high cholesterol, some rare <b>cancers,</b> <b>inherited</b> susceptibility to <b>cancer.</b> A select few are explored below.|$|R
50|$|Only 2 - 4% of {{the cases}} {{presenting}} {{as part of an}} <b>inherited</b> <b>cancer</b> syndrome, as von Hippel-Lindau syndrome.|$|E
50|$|The Menzies Research Institute Tasmania has two {{research}} centres; the Australian Cancer Research Foundation Tasmanian <b>Inherited</b> <b>Cancer</b> Centre and the Wicking Dementia and Research Education Centre.|$|E
50|$|Von Hippel-Lindau {{disease is}} a dominantly <b>inherited</b> <b>cancer</b> {{syndrome}} that massively {{increases the risk of}} various tumors including benign hemangioblastomas and malignant pheochromocytomas, renal cell carcinomas, pancreatic endocrine tumors and endolymphatic sac tumors. It is caused by genetic mutations in the Von Hippel-Lindau tumor suppressor gene. The VHL protein (pVHL) is involved in cellular signalling in oxygen starved (hypoxic) cells. One role of pVHL is to cause the cellular degradation of another protein, HIF1α. Dysfunctional pVHL leads to accumulation of HIF1α, which in turn activates the production of several genes involved in cell growth and blood vessel production (VEGF, PDGFβ, TGFα and erythropoietin).|$|E
40|$|Learning {{together}} in a virtual world. New Poche Centres for Indigenous health at Flinders. New in 2010. Seizures - how do they start? NHMRC Fellowship for congenital heart block research. Can network research help teams in primary health care? Implementing guidelines for prevention in general practice. Predicting and preventing type two diabetes. Improving screening for <b>inherited</b> <b>cancers.</b> Showcasing the entrepreneurial skills of students. Celebrating success in the faculty. Hospital systems affect clinical outcomes. Flinders rewards its emerging best and brightest...|$|R
40|$|Hereditary diffuse {{gastric cancer}} is a genetically {{inherited}} aggressive form of stomach cancer. Once the person is diagnosed as having this gene, they have a 75 %– 80 % chance of <b>inheriting</b> the <b>cancer.</b> People {{who are at risk}} of this genetic mutation have to meet many challenges relating to the implications of the disease. An understanding is required by nurses to guide them in the provision of care for those afflicted with this inherited form of gastric cancer. A review of literature has been undertaken relating to other genetically <b>inherited</b> <b>cancers</b> including hereditary nonpolyposis colon cancer, familial adenomatous polyposis, and hereditary lobular breast cancer. The findings from the literature assist nurses in understanding the physical and psychological implications of genetically inherited cancer; however, further study is required to gain a complete understanding of the implications of hereditary diffuse gastric cancer...|$|R
40|$|Genetic {{counselling}} for familial {{cancer has}} evolved {{as a medical}} speciality relatively recently. Whilst services for families at risk of <b>inherited</b> <b>cancers</b> may be similar to those offered to other families at risk of serious adult-onset conditions, the resource implications are larger due {{to the number of}} families potentially affected. Genetic counsellors can make a considerable contribution to the provision of genetic services for these families. In a longitudinal study of 43 families referred for genetic counselling for a variety of conditions (including cancer), the needs and expectations of clients were explored. Prior to contact with the staff of the genetics service, the majority o...|$|R
50|$|A cancer {{syndrome}} {{or family}} cancer syndrome is a genetic disorder in which inherited genetic mutations {{in one or}} more genes predispose the affected individuals to the development of cancers and may also cause the early onset of these cancers. Cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors. Many of these syndromes are caused by mutations in tumor suppressor genes, genes that are involved in protecting the cell from turning cancerous. Other genes that may be affected are DNA repair genes, oncogenes and genes involved in the production of blood vessels (angiogenesis). Common examples of <b>inherited</b> <b>cancer</b> syndromes are hereditary breast-ovarian cancer syndrome and hereditary non-polyposis colon cancer (Lynch syndrome).|$|E
50|$|The miR-17-92 Cluster {{has been}} implicated in Medulloblastoma (MB) {{which is the most}} common {{paediatric}} malignant brain tumour. It arises when cerebellar granule neurone progenitor (GNP) cells fail to properly migrate and differentiate. MB can be induced by 2 <b>inherited</b> <b>cancer</b> syndromes, one of which is called the Gorlin syndrome and is caused by a mutated PATCHED(PTCH) gene. PTCH is the receptor for Sonic hedgehog (SHH). This SHH signalling pathway is crucial during early development and SSH is the major mitogen for GNP proliferation. Turcots's syndrome can give rise to MB as well, resulting from a mutated adenomatous polyposis coli (APC) gene (a member of the wingless (WNT signalling pathway). But only Gorlin syndrome and the SHH pathway is thought to incorporate the mode of action of the miR-17-92 cluster.|$|E
5000|$|Molecular Epidemiology of Hereditary CancersIn his bio on the Harvard T.H. Chan School of Public Health website, Dr. Li {{said about}} his {{interests}} and work that [...] "recent data have {{established that the}} basic molecular defects in cancer are genetic changes that result in loss of normal cellular control mechanisms. Some of these mutations can be inherited through the germline. I have been studying inherited susceptibility of cancer through affected families. The goal is to identify genes {{that are involved in}} cancer development. I was attracted to studies of cancer families because epidemiological studies show that virtually all cancers manifest a tendency to aggregate in families. Close relatives of a cancer patient are at increased risk of that neoplasm, and perhaps other forms of cancer. The excess site-specific cancer risk is exceptionally high for carriers of certain cancer genes, in whom the attack rate can approach 100 percent. In candidate cancer families, the possibility that clustering is on the basis of chance must be excluded through epidemiological studies that establish the presence of an excess cancer risk. Predisposed families are candidates for laboratory studies to identify the inherited susceptibility factors. These investigations have led to the identification and isolation of human cancer genes, the tumor suppressor genes. These cancer genes are among more than 200 single-gene traits associated with the development of cancer. Approximately a dozen inherited susceptibility genes have been definitively identified, and many more are being sought. From studies of retinoblastoma and other rare cancers, important new information was generated about the fundamental biology of cancers that arise in many patients. Isolation of an <b>inherited</b> <b>cancer</b> susceptibility gene provides opportunities for presymptomatic testing of at-risk relatives. However, testing of healthy individuals also raise important issues regarding informed consent, confidentiality and potential for adverse psychological, social and economic effects...My colleagues and I are using families with inherited mutations in the p53 gene, which predisposes to breast cancer and diverse childhood cancers, as a model for developing a genetic testing program." ...|$|E
30|$|Reasons for {{variations}} in the centres to which referrals are made are speculative but could include referrals to Rhyl reaching a plateau, or a saturation point where the number of referrals likely to be received each year will remain more or less constant in the future. Conjecturally, reasons for this might be that all families with <b>inherited</b> <b>cancers</b> {{have been identified in}} the north Wales catchment area, or all relevant health care professionals in that area are now fully aware of the CGSW. There might alternatively be evidence of an increasing affluence within the Swansea catchment area of mid and south west Wales, as more affluent {{people are more likely to}} be referred. A further reason could be changes in staffing levels across the centres due to natural wastage and new recruitment.|$|R
40|$|Breast {{cancer is}} a multifactorial genenetic disease in which oncogenes derived from normal {{cellular}} genes intervene, which constitute positive signals of cellular proliferation and tumour suppressor genes and represent negative signals of cells multiplication and differentiation. Although these alterations which affect germinal cells produce <b>inherited</b> <b>cancers,</b> {{in most of the}} cases somatic cell genes are affected. To the susceptibility of cancer due to genes as BRCA 1 and BCRA 2, the effect of factors associated to environment, life style and toxic habits are added, these determine a complex interrelation genes-environment which imply an activation of oncogenes and inactivation of tumour suppressors. The objective of this review in to offer an updated view about the main genes implied in breast carcinogenesis. The topic is controversial y currently deeply investigated...|$|R
40|$|Lately, {{understanding}} {{the role of}} cancer stem cells in tumor initiation and progression became a major focus in stem cell biology and in cancer research. Considerable efforts, such as the recent studies by Honeth and colleagues, published in the June issue of Breast Cancer Research, are directed towards developing clinical applications of the cancer stem cell concepts. This work shows that the previously described CD 44 +CD 24 - stem cell phenotype is associated with basal-type breast cancers in human patients, in particular BRCA 1 <b>inherited</b> <b>cancers,</b> but does not correlate with clinical outcome. These very interesting findings caution {{that the success of}} our efforts in translating cancer stem cell research into clinical practice depends on how thorough and rigorous we are at characterizing these cells. The cancer stem cell model, a concept initially propose...|$|R
5000|$|In [...] "Babes In Toyland", Silver gets {{accepted}} into New York University and hopes {{she will be}} close to Navid in nearby Princeton, but she later has second thoughts. In Blood Is Thicker Than Mud, Silver, working as a production assistant {{on the set of}} Liam's latest movie, confides in him about her fears of having an <b>inherited</b> <b>cancer</b> gene. In The Heart Will Go On, Liam finds himself accompanying Silver to a clinic at the hospital to support her during a test to detect if she has the breast cancer gene, while Vanessa becomes increasingly jealous over the time Liam is spending with Silver and his refusal to explain why. In Blue Ivy, Silver and Liam have sex after she knows her test results are positive for the cancer gene. In Bride and Prejudice, Silver wakes up in Liam’s bed from when she ran into his arms after her breast cancer gene diagnosis. Liam admits his feelings for Silver, but she wants to forget the whole night happened. Then, in a string of odd interactions, Silver all of a sudden decides she wants to rekindle things with Navid and seems to go {{out of her way to}} express her feelings to Navid right in front of Liam. It’s clear that she has feelings for Liam. But in the end, Navid is committed to staying with Silver while Liam won’t let Silver get away that easily— he kisses her, again. In Tis Pity, Silver is still determined to make a relationship with Navid work out. Navid is now Silver’s doting boyfriend and support system again, so he goes with Silver to her first mammogram after learning she has the breast cancer gene. At this appointment, Silver realizes she may be pregnant. Since Navid knows this possible baby could not be his, he wisely names himself “most likely to raise a stranger’s baby” considering his track record with Ade back in high school and now this situation. Navid also lets the possibility slip to Liam, since they are bros and Navid has no clue Liam is the potential baby-daddy. Of course the confusion and emotions spiral out of control very quickly at Liam’s movie premiere. With cameras flashing, the boys come to blows when Navid puts two and two together. Even though Silver learns she is not in fact pregnant, the cat is out of the bag. In A Tale of Two Parties, Silver goes to her doctor for an appointment, and the doctor tells her she has a lot of choices. One of them is deciding to have her ovaries removed after she has kids, raising the risk for her to have ovarian cancer. Later on, Silver thinks about wanting to have a baby. While at the Max's brides bachelorette party, Silver asks Adrianna what it was like being pregnant. Ade tells her it was the most amazing experience of her life. Silver tells her about the missing feeling she had after she found out her pregnancy was a false alarm. Silver decides she wants a baby and asks Liam & Navid if either of them wants to raise one with her. In the season finale, Forever Hold Your Peace, Silver has vehemently decided that she wants to get pregnant sooner rather than later to ensure that she can have a child before preventative cancer treatments. She wants a friend who she can always count on to be in her life and be the father of her child. She picks her best friend Teddy.|$|E
40|$|Mendelian {{causes of}} <b>inherited</b> <b>cancer</b> {{susceptibility}} are mostly rare and characterized by variable expression and incomplete penetrance. Phenotypic variability {{may result from}} a range of causes including locus heterogeneity, allelic heterogeneity, genetic and environmental modifier effects, or chance. Another potential cause is the presence of 2 or more <b>inherited</b> <b>cancer</b> predisposition alleles in the same individual. Although the frequency of such occurrences might be predicted to be low, such cases have probably been underascertained because standard clinical practice has been to test candidate <b>inherited</b> <b>cancer</b> genes sequentially until a pathogenic mutation is detected. However, recent advances in next-generation sequencing technologies now provide the opportunity to perform simultaneous parallel testing of large numbers of <b>inherited</b> <b>cancer</b> genes. Herein we provide examples of patients who harbor pathogenic mutations in multiple <b>inherited</b> <b>cancer</b> genes and review previously published examples to illustrate the complex genotype-phenotype relationships in these cases. We suggest that clinicians should proactively consider the likelihood of this phenomenon (referred to herein as multilocus inherited neoplasia alleles syndrome [MINAS]) in patients with unusual <b>inherited</b> <b>cancer</b> syndrome phenotypes. To facilitate the clinical management of novel cases of MINAS, we have established a database to collect information on what is likely to be an increasingly recognized cohort of such individuals...|$|E
30|$|Furthermore, {{with the}} {{increasing}} use of germline panel testing for <b>inherited</b> <b>cancer</b> syndromes, there is a clinical need for correlation between genotype and phenotype. We recommend that large databases such as SEER consider collecting data on BRCA 1 and BRCA 2 and other <b>inherited</b> <b>cancer</b> predisposition genes, since the large clinical information available in SEER provides an excellent opportunity for {{a better understanding of the}} risk of SM based on specific DNA repair genes.|$|E
40|$|Retinoblastoma {{represents}} the prototypic model for <b>inherited</b> <b>cancers.</b> The RB 1 gene {{was the first}} tumor suppressor gene to be identified. It {{represents the}} most frequent primary eye cancer in children under 15 years old, habitually occurring in infancy, even in utero, but {{can be observed in}} older children or young adults. Many other retinal lesions may also simulate retinoblastoma. The two major presenting signs are leukocoria and strabismus, but other ocular or general signs may be observed. A highly malignant tumor, retinoblastoma can nowadays be cured. The heritable form, however, carries a high risk of second nonocular tumors. Treatment {{in the early stages of}} disease holds a good prognosis for survival and salvage of visual function. In very late stages, however, the prognosis for ocular function and even survival is jeopardized...|$|R
40|$|Fact {{sheet on}} {{the breast cancer}} risk of inheritanceAll breast cancer results from {{multiple}} gene mutations. The initial mutation can be inherited from one's parents (familial breast cancer) or occur after conception (sporadic breast <b>cancer).</b> <b>Inherited</b> gene mutations {{play a role in}} about twenty-seven percent of all cases of breast cancer. Mutations in the genes BRCA 1 and BRCA 2 have been associated with early breast cancer in some families. But these families are rare and are thought to account for only about four percent of all breast <b>cancer</b> cases. Most <b>inherited</b> breast <b>cancer</b> risk results from the interaction of several mutated genes. Families with this pattern of inheritance will contain only a few members with breast cancer. These mutated genes by themselves are associated with only a small increase in breast cancer risk, but when several of these genes are inherited together they can lead to a significant increase in breast cancer risk. Diet and lifestyle may modify <b>inherited</b> breast <b>cancer</b> risk but more study is needed to identify and understand how this happens. United States Department of Agriculture CSREES, the New York State Department of Health and Department of Environmental Conservation, and Cornell Universit...|$|R
40|$|Abstract: The {{concept of}} the adenoma-carcinoma sequence, as first espoused by Morson et al. whereby the {{development}} of colorectal cancer is dependent on a stepwise progression from adenomatous polyp to carcinoma is well documented. Initial studies of the genetics of <b>inherited</b> colorectal <b>cancer</b> susceptibility concentrated on the <b>inherited</b> colorectal <b>cancer</b> syndromes, such as Familial Adenomatous Polyposis (FAP) and Lynch Syndrome (also known as HNPCC). These syn-dromes, whilst easily characterisable, have a well understood sequence of genetic mutations that predispose the sufferer to developing colorectal cancer, initiated for example in FAP {{by the loss of}} the second, normal allelle of the tumour supres-sor APC gene. Later research has identified other inherited variants such as MUTYH (MYH) polyposis and Hyperplastic Polyposis Syndrome. Recent research has concentrated on the pathways by which colorectal adenomatous polyps not due to one of these known inherited susceptibilities undergo malignant transformation, and determination of the types of polyps most likely to do so. Also, why do individuals in certain families have a predisposition to colorectal cancer. In this article, we will discuss briefly the current state of knowledge of the genomics of the classical <b>inherited</b> colorectal <b>cancer</b> syndromes. We will also discuss in detail the genetic changes in polyps that undergo malignant transformation as well as current knowledge with regards to the epigenomic changes found in colorectal polyps...|$|R
40|$|The Use of Academic-Community Partnerships in Participant Accrual to an <b>Inherited</b> <b>Cancer</b> RegistryDevon Bonner, Patrice Fleming, Sue Friedman, Susan Vadaparampil, Veronica Harville, Tuya PalBackground: The {{development}} of <b>inherited</b> <b>cancer</b> registries has provided for increased ascertainment of participants into genetic-based cancer research studies. Participants have mainly been recruited through academic-based genetic counseling and testing services. An <b>Inherited</b> <b>Cancer</b> Registry (ICARE) was established at Moffitt Cancer Center and {{participants were recruited}} through both an academic-community partnership with Facing Our Risks Empowered (FORCE), a non-profit organization for individuals and families affected by hereditary breast and ovarian cancer, and through academic-based high risk cancer clinics. This study sought to determine the efficacy of both methods in recruiting participants to the ICARE <b>inherited</b> <b>cancer</b> registry. Methods: Data was collected from a pre-existing dataset tracking accrual into the ICARE registry from June 2010 to November 2010. Frequencies were calculated {{for the number of}} participants accrued through each recruitment method as well as the number of subjects approached and number of participants consented to the registry through each method. Results: Of the 128 participants enrolled into ICARE, 82 % (n= 105) were enrolled through the academic-community partnership and 18 % (n= 23) were enrolled through the academic-based high risk cancer clinics. Of the 148 subjects approached for enrollment, 81 % (n= 116) were approached through the academic-community partnership and 19 % (n= 27) were approached through the academic-based high risk cancer clinics. 90. 5 % of subjects approached through the academic-community partnership were enrolled in the cancer registry while 85 % of subjects approached through academic-based high risk cancer clinics enrolled. Conclusions: Although <b>inherited</b> <b>cancer</b> registries have historically recruited heavily through academic-based clinical services, recruitment through academic-community partnerships may prove to be a valuable tool in accruing registry participants as well...|$|E
30|$|Testing {{for genetic}} {{predisposition}} to <b>inherited</b> <b>cancer</b> syndromes is evolving rapidly (Tung et al. 2015); however, {{black women are}} under-represented in studies evaluating <b>inherited</b> <b>cancer</b> syndromes. In the study by Tung et al. (2015), black women represented only approximately 5  % of the individuals tested. Our finding that black women are at {{an increased risk of}} second cancer suggests that this population would likely benefit from more genetic evaluation and counseling after a primary breast cancer diagnosis. Race is currently not a factor in NCCN guidelines for genetic counseling, but based on our findings, consideration should be given towards including race in evaluating genetic breast cancer risk.|$|E
40|$|Summary. The {{mammalian}} {{target of}} rapamycin (mTOR) {{is a highly}} conserved serine/threonine protein kinase that regulates a number of diverse biologic processes important for cell growth and proliferation, including ribosomal biogenesis and protein translation. In this regard, hyperactivation of the mTOR signaling pathway has been demonstrated in numerous human cancers, including a number of <b>inherited</b> <b>cancer</b> syndromes in which individuals have {{an increased risk of}} developing benign and malignant tumors. Three of these <b>inherited</b> <b>cancer</b> syndromes (Lhermitte-Duclos disease, neurofibromatosis type 1, and tuberous sclerosis complex) are characterized by significant central nervous system dysfunction and brain tumor formation. Each of these disorders is caused by a genetic mutation that disrupts the expression of proteins which negatively regulate mTOR signaling, indicating that the mTOR signaling pathway is critical for appropriate brain development and function. In this review, we discuss our current understanding of the mTOR signaling pathway and its role in promoting ribosome biogenesis and cell growth. We suggest that studies of this pathway may prove useful in identifying molecular targets for biologically-based therapies of brain tumors associated with these <b>inherited</b> <b>cancer</b> syndromes as well as sporadic central nervous system tumors...|$|E
40|$|In {{the immune}} system, many {{tolerance}} checkpoints exist to prevent self-antigens from stimulating the relentless growth of self-reactive B and T lymphocytes. The genes and molecular pathways underpinning these checkpoints overlap with {{those involved in}} tumor suppression. As with an <b>inherited</b> predisposition to <b>cancer,</b> <b>inherited</b> defects in self-tolerance genes typically precipitate autoimmune disease stochastically after a latent phase. Multiple mutations, inherited and somatic, may be needed before a self-reactive clone bypasses sequential tolerance checkpoints resulting {{in the emergence of}} autoimmune disease...|$|R
40|$|Familial {{breast cancer}} has been {{recognised}} for many years. In the 1990 s the genetic mechanism of inheritance of {{a proportion of}} these familial cancers {{was found to be}} attributable to germline mutation in either of two newly discovered genes, namely BRCA 1 and BRCA 2. Since the discovery of these genes, studies have been performed in which the pathological characteristics of familial cancers arising in patients with germline BRCA 1 and BRCA 2 mutation have been examined. A distinct pathological phenotype of high-grade, oestrogen receptor-negative breast cancer, often with medullary features, has been consistently described for BRCA 1 cancers. A less distinct phenotype has been described for BRCA 2 cancers. The discovery of genotype-phenotype correlation has significant implications for patient management and novel treatment strategies, not only for <b>inherited</b> <b>cancers,</b> but for breast cancer in general...|$|R
40|$|Includes bibliographical {{references}} (leaves 134 - 145). Predictive {{genetic testing}} for hereditary nonpolyposis colorectal cancer (HNPC) {{has been offered}} to families with known mutations in South Africa since 1997. The {{aim of this study}} is to evaluate the benefits and limitations, as perceived by family members, of the current management of <b>inherited</b> colorectal <b>cancer...</b>|$|R
40|$|Difficulties {{faced by}} primary care {{physicians}} as they increase their responsibility for the diagnosis of <b>inherited</b> <b>cancer</b> risk include issues of cognitive strategy, the context of care, and cultural and institutional factors. Charateristics common to many genetic disorders—such as rarity, variability, implications for relatives, and temporal pattern—render our usual cognitive strategies less effective. Constraints of managed care, care teams, and high turnover of panels create a particularly difficult context {{for the care of}} people at risk for <b>inherited</b> <b>cancer.</b> Echoes of the eugenics movement, the implications of expanding genetic knowledge, and con-cerns about discrimination all complicate collaborative clinical decision making. Eight strategies are suggested to cope with these barriers to diagnosis. Primary care physicians also face challenges managing patients identified as at increased risk for <b>inherited</b> <b>cancer.</b> These include confidentiality, coordination and communication. Concerns for protecting the patient’s confidentiality can inadvertently leave pri-mary care physicians with partial information. Coordination is complicated when multiple organ systems and individuals are at risk, and knowledgable specialty centers may be distant. Communication requires sensitivity and skill in translating complex concepts from molecular biology and statistics into lay terms. Seven strategies are suggested to help with management. Cancer 1999; 86 : 2583 – 8. © 1999 American Cancer Society...|$|E
40|$|BACKGROUND Recent {{evidence}} has shown low and inconsistent rates of family history screening among generalist physicians. Little {{has been done}} to investigate the physician factors likely to mediate this behavior. We investigated family physicians’ beliefs about screening their patients for <b>inherited</b> <b>cancer</b> risk, measuring their perceptions of self-efficacy and the importance of screening...|$|E
40|$|Background: Clinically {{relevant}} genetics {{knowledge is}} essential for appropriate assessment and management of <b>inherited</b> <b>cancer</b> risk, and for effective communication with patients. This national physician survey assessed knowledge regarding basic cancer genetics concepts early {{in the process of}} introduction of predictive genetic testing for breast/ovarian and hereditary non-polyposis colorectal cancer (HNPCC) syndromes...|$|E
40|$|Introduction: Akt {{activation}} {{is involved}} in the pathogenesis of <b>inherited</b> thyroid <b>cancer</b> in Cowden's syndrome and in sporadic thyroid cancers. In cell culture, Akt regulates thyroid cell growth and survival; but recent data suggest that Akt also regulates cell motility in non-thyroid cell lines. We therefore sought to evaluate the role of Akt in thyroid cancer progression...|$|R
40|$|Although uncommon, {{breast cancer}} in young women is worthy of special {{attention}} due to the unique and complex issues that are raised. This article reviews specific challenges associated with the care of younger breast cancer patients, which include fertility preservation, management of <b>inherited</b> breast <b>cancer</b> syndromes, maintenance of bone health, secondary prevention, and attention to psychosocial issues...|$|R
40|$|In {{the last}} decade, {{it has become}} {{apparent}} that not only DNA sequence variations but also epigenetic modifications may contribute to disease, including cancer. These epigenetic modifications involve histone modification including acetylation and methylation, DNA methylation, and chromatin remodeling. One of the best-characterized epigenetic changes is aberrant methylation of cytosines that occur in so-called CpG islands. DNA hypomethylation, prevalent as a genome-wide event, usually occurs in more advanced stages of tumor development. In contrast, DNA hypermethylation is often observed as a discrete, targeted event within tumor cells, resulting in specific loss of gene expression. Interestingly, {{it was found that}} sporadic and <b>inherited</b> <b>cancers</b> may exhibit similar DNA methylation patterns, and many genes that are mutated in familial cancers have also been found to be hypermethylated, mutated, or deleted in sporadic cancers. In this review, we will focus on DNA methylation events as heritable epimutations predisposing to colorectal cancer development...|$|R
